10-K: Vanda Pharmaceuticals Reports Wider Loss Amid HETLIOZ Generic Competition and Increased R&D

Vanda Pharmaceuticals reported a significantly wider net loss in 2025, driven by increased R&D and commercialization expenses, despite new product approvals and growth in Fanapt sales.

Summary

• Total revenues increased by 9% to $216.1 million in 2025, up from $198.8 million in 2024.
• Fanapt net product sales grew by 24% to $117.3 million in 2025, primarily due to increased volume and the commercial launch for bipolar I disorder in Q3 2024.
• HETLIOZ net product sales decreased by 7% to $71.4 million in 2025, impacted by generic competition in the U.S.
• PONVORY net product sales saw a slight decrease of 2% to $27.4 million in 2025, following its commercial launch in RMS in Q3 2024.
• Net loss significantly widened to $220.5 million in 2025, compared to a net loss of $18.9 million in 2024.
• Research and development expenses surged by 47% to $109.3 million in 2025, mainly due to the imsidolimab license payment and increased Fanapt/Bysanti development.
• Selling, general and administrative expenses increased by 63% to $238.0 million in 2025, driven by commercial launches for Fanapt in bipolar disorder and PONVORY in RMS.
• A non-cash income tax expense of $113.7 million was recorded in 2025 due to a valuation allowance against all deferred tax assets.
• Cash, cash equivalents, and marketable securities decreased to $263.8 million as of December 31, 2025, from $374.6 million at December 31, 2024.
• NEREUS TM received FDA approval in December 2025 for the prevention of vomiting induced by motion and showed positive results in a clinical study for GLP-1 receptor agonist-induced vomiting.
• The Bysanti TM NDA for bipolar I disorder and schizophrenia is under FDA review with a PDUFA target action date of February 21, 2026.
• The Imsidolimab BLA for generalized pustular psoriasis (GPP) was submitted to the FDA in Q4 2025 with a request for priority review.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for Vanda Pharmaceuticals, marked by significant financial losses and regulatory hurdles, despite some positive product developments. The substantial cash burn and ongoing litigation create considerable uncertainty.

Positives

• Fanapt net product sales increased by 24% to $117.3 million in 2025, with total prescriptions up 28% and new to brand prescriptions up 149% for the full year.
• NEREUS TM received FDA approval in December 2025 for the prevention of vomiting induced by motion, adding a new commercial product to the portfolio.
• Positive clinical study results for NEREUS TM in preventing vomiting induced by GLP-1 receptor agonists (Wegovy), with a Phase III program anticipated in H1 2026.
• Bysanti TM NDA for bipolar I disorder and schizophrenia is under FDA review with a PDUFA target action date of February 21, 2026, indicating potential near-term approval.
• Imsidolimab BLA for generalized pustular psoriasis (GPP) was submitted to the FDA in Q4 2025, with priority review requested, potentially accelerating market entry.
• Initiated Phase III studies for Fanapt LAI in schizophrenia, Bysanti TM in MDD, PONVORY in psoriasis and ulcerative colitis, and VQW-765 in social anxiety disorder, expanding the development pipeline.
• VTR-297 Phase I clinical study for onychomycosis is fully enrolled, and VPO-227 for cholera is in Phase I with Orphan Drug Designation.

Negatives

• Net loss significantly widened to $220.5 million in 2025 from $18.9 million in 2024, indicating a substantial deterioration in profitability.
• HETLIOZ net product sales decreased by 7% to $71.4 million in 2025, primarily due to generic competition in the U.S. market.
• Research and development expenses increased by 47% to $109.3 million, contributing to the wider net loss.
• Selling, general and administrative expenses increased by 63% to $238.0 million, reflecting high commercialization costs for new launches.
• A non-cash income tax expense of $113.7 million was recorded due to a valuation allowance against deferred tax assets, impacting reported earnings.
• Cash, cash equivalents, and marketable securities decreased by $110.8 million, indicating significant cash burn.
• FDA re-review of HETLIOZ sNDA for jet lag disorder again determined it cannot be approved in its current form, prolonging regulatory uncertainty.
• HETLIOZ sNDA for insomnia received a Complete Response Letter (CRL) and a proposed order denying a hearing, indicating further regulatory hurdles.
• NEREUS TM NDA for gastroparesis received a CRL from the FDA, with the FDA not viewing the data as substantial evidence of efficacy for any indication or length of treatment.
• Ongoing patent litigation for HETLIOZ and HETLIOZ LQ against generic manufacturers, with some prior rulings against the company, poses continued risk to sales.

Risks

• Dependence on the commercial success of Fanapt, HETLIOZ, PONVORY, and NEREUS TM, with generic competition for HETLIOZ already impacting sales.
• Uncertainty relating to pricing and reimbursement policies in the U.S., including the Inflation Reduction Act of 2022 (IRA) and the One Big Beautiful Bill Act (OBBBA), which could limit product commercial success.
• Risk of FDA not approving NDA filing for NEREUS TM for gastroparesis or sNDAs for HETLIOZ for jet lag disorder or insomnia.
• Failure to obtain necessary regulatory approvals for current product candidates, including Bysanti TM and imsidolimab.
• Disruptions at the FDA and other government agencies, including potential government shutdowns, could delay product development and approval.
• Global economic conditions, including inflation and interest rate increases, may adversely affect business operations and access to capital.
• Reliance on a limited number of third-party manufacturers and specialty pharmacies for product supply and distribution, posing risks of disruption.
• Substantial competition from larger pharmaceutical companies and generic products, which may develop or commercialize products more successfully.
• Potential for undesirable side effects or other properties of products that could delay, prevent, or revoke regulatory approval or limit marketability.
• Clinical trials are expensive and their outcomes are uncertain, with potential for failure or delays in completion.
• Inability to achieve sustained profitability due to significant research and development and commercialization expenditures.
• Limitations on the ability to use net operating loss (NOL) and tax credit carryforwards to offset future taxable income due to ownership changes.
• Product liability lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential.
• Strict price controls in E.U. Member States may delay or prevent commercial launch or impede commercial success of HETLIOZ in Europe.
• Stringent and evolving laws, rules, and regulations regarding data privacy and security in foreign jurisdictions (e.g., GDPR) could result in claims, penalties, or increased costs.
• Intellectual property infringement claims or challenges to patent validity could be expensive, time-consuming, and unsuccessful.
• Stock price volatility due to various factors, including litigation outcomes, regulatory developments, and changes in financial results.
• Cybersecurity breaches could expose the company to liability, damage reputation, or compromise confidential information.
• Risks associated with artificial intelligence, including security risks and an uncertain regulatory environment.

Future Outlook

The company anticipates continued significant research and development expenses as it develops its pipeline and expands commercial activities. Future cash requirements will depend on regulatory approvals for Bysanti TM and imsidolimab, revenue generation, and the scope of commercial and development programs. The company believes existing funds and product sales will be sufficient for at least the next 12 months, but may need additional capital. The impact of the Inflation Reduction Act on the pharmaceutical industry is likely to be significant, and the company expects continued pricing pressures and healthcare reform measures.

Management Comments

• Fanapt experienced significant growth, with total prescriptions (TRx) increasing by 36% and Fanapt net product sales increasing by 25% in the fourth quarter of 2025 as compared to the fourth quarter of 2024.
• Fanapt total prescriptions increased by 28% and Fanapt net product sales increased by 24% for the full year 2025 as compared to the full year 2024.
• New to brand prescriptions (NBRx) increased by 108% in the fourth quarter of 2025 as compared to the fourth quarter of 2024 and increased by 149% for the full year 2025 as compared to the full year 2024.
• During 2025, our direct-to-consumer campaign, launched in the first quarter, continued to drive meaningful gains in brand awareness for us and our products, Fanapt and PONVORY.
• Fanapt performance remains the focus of our commercial initiatives and encourages us to continue to invest in this differentiated medicine, and, if approved, the franchise-extending launch of Bysanti TM.
• We believe that Bysanti TM represents a potential improvement over the clinical profile of Fanapt and has the potential to create sustained, long-term value in the treatment of psychiatric disorders.
• We believe that NEREUS TM has a well-established safety profile, as demonstrated by the results of extensive testing in animals and humans.
• NEREUS TM is the first novel drug to be accepted for review by the FDA for gastroparesis in over 30 years and, if approved, will be the first novel drug to be approved by the FDA for the treatment of gastroparesis in over 40 years.
• We believe that the ownership change in 2014 will not impact our ability to utilize NOL and credit carryforwards; however, future ownership changes may cause our existing tax attributes to have additional limitations.

Industry Context

StockSavvy.ai notes that Vanda Pharmaceuticals operates in a highly competitive biopharmaceutical landscape, characterized by significant R&D investment and intense generic competition. The company's focus on CNS disorders (schizophrenia, bipolar I, sleep-wake disorders) and rare diseases aligns with a trend towards specialized therapies. However, the substantial increase in SG&A expenses for commercial launches and the impact of generic HETLIOZ sales highlight the challenges of market penetration and intellectual property defense in this sector. The ongoing regulatory disputes with the FDA for HETLIOZ and NEREUS TM reflect the stringent and often contentious nature of drug approval processes, particularly for novel indications or in the face of generic challenges. The mention of the Inflation Reduction Act and the One Big Beautiful Bill Act underscores the increasing pressure on drug pricing and reimbursement across the U.S. healthcare industry, a trend that will likely continue to shape pharmaceutical companies' commercial strategies and profitability.

Comparison to Industry Standards

• For Fanapt, competitors include other atypical and typical antipsychotics, such as Abilify (aripiprazole), Zyprexa (olanzapine), Seroquel (quetiapine), and Risperdal (risperidone), which are well-established in the schizophrenia and bipolar disorder markets. Fanapt's 24% sales growth in 2025 is strong, especially with its recent bipolar I disorder launch, suggesting effective market penetration in a competitive segment.
• For HETLIOZ, while it was the first FDA-approved treatment for Non-24 and SMS, the 7% sales decline in 2025 due to generic competition (Teva, Apotex, MSN) is a common industry challenge for branded drugs losing patent exclusivity. This mirrors the typical erosion seen when generics enter the market, often leading to significant price and volume pressure.
• PONVORY competes in the relapsing forms of multiple sclerosis (RMS) market against other sphingosine 1-phosphate (S1P) receptor modulators like Gilenya (fingolimod) and Mayzent (siponimod), as well as other immune-modulating therapies. Its slight sales decrease of 2% in its early commercialization phase (post-acquisition) suggests a challenging entry into a crowded and mature market.
• NEREUS TM's approval for motion sickness and positive GLP-1 induced vomiting data positions it against existing antiemetics and motion sickness treatments like scopolamine patches, ondansetron, and promethazine. Its potential as the first novel drug for gastroparesis in decades, despite the CRL, indicates a high unmet need, but also the high bar for FDA approval in such areas.
• The company's R&D spending increase of 47% to $109.3 million, particularly for pipeline assets like Bysanti TM and imsidolimab, is consistent with biopharmaceutical companies investing heavily in late-stage clinical development and new acquisitions to drive future growth, especially when facing generic erosion of existing products.

Corporate Governance

Legal Proceedings

• Ongoing Hatch-Waxman lawsuits against Teva and Apotex in Delaware District Court asserting infringement of U.S. Patent No. 11,285,129 and U.S. Patent No. 11,918,556 for HETLIOZ, with a trial scheduled for August 3, 2026.
• Ongoing Hatch-Waxman lawsuit against MSN in Delaware District Court asserting infringement of multiple U.S. patents for HETLIOZ LQ, with a trial scheduled for September 14, 2026, and a 30-month stay until December 3, 2026.
• Appeal to the U.S. Court of Appeals for the District of Columbia Circuit regarding the FDA's approval of Teva's generic HETLIOZ capsules (Braille labeling issue), with oral argument scheduled for March 12, 2026.
• Lawsuit against the FDA in DC District Court challenging the FDA's approval of MSN's ANDA for generic HETLIOZ capsules (bioequivalence and Appointments Clause claims), currently stayed pending resolution of an agency appeal.
• Appeal to the Delaware District Court regarding false advertising and unfair competition claims against MSN, Amneal, and Impax related to generic HETLIOZ.
• Lawsuit against the FDA in DC District Court regarding the HETLIOZ sNDA for jet lag disorder, where the DC Circuit ruled in Vanda's favor in August 2025, remanding the case, but the FDA again denied approval in January 2026, leading to a renewed request for hearing.
• Petition for review in the U.S. Court of Appeals for the DC Circuit seeking review of the FDA's final order refusing to hold a hearing or approve the HETLIOZ sNDA for insomnia.
• Lawsuit against the FDA in DC District Court challenging the FDA's decision-makers authority under the Appointments Clause regarding the NEREUS TM NDA for gastroparesis, which remains pending.
• Appeal to the U.S. Court of Appeals for the Federal Circuit regarding a takings claim against the federal government for uncompensated taking and misuse of trade secrets related to HETLIOZ and Fanapt.

Stakeholder Impact

• Shareholders: Face significant dilution risk if additional equity financing is pursued. Stock price volatility is a concern due to ongoing litigation, regulatory setbacks, and financial performance. The increased net loss and cash burn could negatively impact investor confidence.
• Employees: The company increased its workforce by 45% in 2025, indicating growth in operations and potential for career opportunities. However, financial losses and strategic shifts could impact future employment stability.
• Customers (Wholesalers, Specialty Pharmacies, Distributors): Concentration of revenues with a limited number of customers creates dependency and potential for revenue fluctuations based on their buying patterns.
• Patients: New product approvals (NEREUS TM for motion sickness) and pipeline advancements (Bysanti TM, imsidolimab) offer potential new treatment options. However, delays in regulatory approvals for other indications (HETLIOZ for jet lag/insomnia, NEREUS TM for gastroparesis) mean patients may wait longer for needed therapies. Generic competition for HETLIOZ could lead to more affordable options but also impacts the innovator's ability to invest in market education.
• Licensors (BMS, Lilly, Anaptys, UCSF, Novartis, OliPass): Continue to receive milestone payments and royalties based on product development and sales, but regulatory setbacks or commercial underperformance could affect future payments.

Next Steps

• Resume hearing proceedings with the FDA Commissioner regarding the HETLIOZ sNDA for jet lag disorder.
• Continue to pursue FDA approval for HETLIOZ for the treatment of insomnia, including ongoing legal challenges.
• Initiate a Phase III clinical program for NEREUS TM for the prevention of vomiting induced by GLP-1 receptor agonists in the first half of 2026.
• Continue to pursue marketing authorization for NEREUS TM for gastroparesis, including ongoing legal challenges with the FDA.
• Await PDUFA target action date of February 21, 2026, for Bysanti TM NDA for bipolar I disorder and schizophrenia.
• Continue enrolling patients in the Phase III clinical study for Bysanti TM as an adjunctive treatment for MDD, with results expected in 2026.
• Continue Phase III clinical studies for PONVORY for the treatment of psoriasis and ulcerative colitis.
• Continue Phase III program for VQW-765 in the treatment of adults with social anxiety disorder, with study results expected by the end of 2026.
• Continue Phase III study of the LAI formulation of Fanapt in the treatment of schizophrenia in relapse-prevention.
• Continue clinical study of the LAI formulation of Fanapt in people with treatment-resistant hypertension.
• Continue enrollment in the Phase I/II clinical study of VTR-297 in hematologic malignancies.
• Continue clinical program for VSJ-110 for the treatment of allergic conjunctivitis and proof of concept study for dry eye disease.
• Continue Phase I study of VPO-227 for the treatment of cholera in Bangladesh.
• Continue to vigorously enforce intellectual property rights related to HETLIOZ and HETLIOZ LQ through ongoing patent litigation.

Key Dates

Recommendation

Vanda Pharmaceuticals presents a mixed outlook. The company has demonstrated strong growth in Fanapt sales and secured a new FDA approval for NEREUS TM, alongside advancing a diverse pipeline including Bysanti TM and imsidolimab. These are positive indicators for future revenue streams. However, the significant increase in net loss, substantial cash burn, and the negative impact of generic competition on HETLIOZ sales are major concerns. Furthermore, multiple ongoing regulatory disputes and patent litigations introduce considerable uncertainty and potential for further financial and operational setbacks. A seasoned investor would likely 'hold' to monitor the outcomes of these critical legal and regulatory challenges, as well as the commercial ramp-up of newly approved products and pipeline advancements, before making a more definitive investment decision.

Keywords

Biopharmaceutical, Schizophrenia, Bipolar I Disorder, Non-24-Hour Sleep-Wake Disorder, Smith-Magenis Syndrome, Multiple Sclerosis, Motion Sickness, Gastroparesis, Generalized Pustular Psoriasis, Major Depressive Disorder, Jet Lag Disorder, Insomnia, Orphan Drug, FDA Approval, Clinical Trials, Patent Litigation, Generic Competition, SEC Filing, Drug Development, Pharmacogenetics, Pharmacogenomics, Rare Diseases, CNS Disorders, Autoimmune Disorders, Oncology, Ophthalmology, Gastroenterology, Dermatology, Neurology, Cardiovascular, Hematology, Gene Therapy, ASO, CFTR, HDAC Inhibitor, S1P Receptor Modulator, NK-1 Receptor Antagonist, IL-36R Antagonist, Commercialization, Healthcare Reform, Inflation Reduction Act, Cybersecurity